Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.

Life sciences - 15 Aug 2017

Hong Sung Pyo, Ahn Soon Kil

Abstract excerpt

AIMS: BRAF mutations, especially BRAF V600E, are a frequent occurrence in malignant melanomas. The BRAF inhibitors are used as the care standard for BRAF-mutant metastatic melanomas. However, melanomas rapidly develop resistance to BRAF inhibitors after a median response duration of 6months, and the subsequent rapid development of cutaneous toxicity is enhanced by the paradoxical activation of CRAF. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to MAP Kinase Signaling System
Share to Melanoma
Share to Mice, Inbred ICR

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Purines

Share to Rats, Sprague-Dawley

Share to Sulfonamides

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28645859
DOI: 10.1016/j.lfs.2017.06.021

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.PMID 28645859Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Semantic proximity Read ↗

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.Semantic proximity Read ↗

Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.Semantic proximity Read ↗

Mechanism and consequences of RAF kinase activation by small-molecule inhibitorsSemantic proximity Read ↗

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.Semantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.